시장보고서
상품코드
1283947

세계의 정맥주사제 시장 규모, 시장 점유율, 용도 분석, 지역별 전망, 성장 동향, 주요 기업, 경쟁 전략 및 예측(2023-2031년)

Intravenous Solutions Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 To 2031

발행일: | 리서치사: Acute Market Reports | 페이지 정보: 영문 115 Pages | 배송안내 : 1-2일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

정맥주사제 시장은 2031년까지 8.0%를 나타낼 것으로 예상됩니다. 정맥주사제는 환자가 필요한 영양을 섭취할 수 있도록 다양한 영양소 조합을 제공합니다. 정맥주사제 세계 수요는 견조한 성장세를 보이고 있으며, 아시아태평양에서 높은 성장세를 보이고 있습니다. 정맥주사 제품은 품질과 가용성을 보장하기 위해 고도로 규제되고 있습니다. 성숙한 시장이지만 지속적으로 진화하고 있기 때문에 안정적인 성장세를 보이고 있습니다.

정맥주사제 분야의 제조업체와 공급업체들은 제품의 특성과 판매 및 유통 방식을 지속적으로 개선하고 있습니다. 일부 대형 기업들은 직판부서, 독립 유통업체, 소매업체 및 도매업체를 고용하고 있습니다. 또한 제조업체들은 수익성을 유지하기 위해 대체 공급 방식을 채택하고 있습니다. 신흥국 시장에서는 제조업체를 대신해 제품을 보관하고 배송하는 제3자가 큰 발판을 마련하고 있습니다. 이러한 유형공급업체는 항상 충분한 재고를 확보하여 신속한 고객 서비스를 제공할 수 있습니다. 이 시장의 다른 판매 방법으로는 고객 및 판매 서비스 담당자를 통한 판매, 카탈로그 배포 및 머천다이징, 전자 구매 기능 및 관련 혜택, 이메일 캠페인, 산업 신문 및 무역 박람회 등을 통한 홍보 등이 있습니다.

시장 진출 기업

Amanta Healthcare Ltd., Axa Parenterals Ltd., B. Braun Melsungen AG, Baxter International Inc. Healthcare Pvt Ltd., Fresenius Kabi AG, Grifols S.A, Henry Schein Inc. Ltd, Salius Pharma Private Limited, Sichuan Kelun Pharmaceutical Co. Ltd, Soxa Formulations & Research(Pvt.) Ltd, Vifor Pharma Management Ltd.

목차

제1장 서문

  • 보고서의 내용
    • 보고서의 목적
    • 대상 독자
    • 주요 제공 상품
  • 시장 세분화
  • 조사 방법
    • 단계 Ⅰ - 2차 조사
    • 단계 Ⅱ - 1차 조사
    • 단계 Ⅲ - 전문가 패널 리뷰
    • 전제조건
    • 채택한 접근

제2장 주요 요약

제3장 정맥주사제시장 : 경쟁 분석

  • 주요 벤더의 시장 포지셔닝
  • 벤더가 채택하는 전략
  • 주요 산업 전략
  • Tier 분석 : 2022 vs. 2031

제4장 정맥주사제시장 : 매크로 분석과 시장 역학

  • 서론
  • 세계의 정맥주사제매출, 2021-2031
  • 시장 역학
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 주요 과제
    • 주요 기회
  • 성장 촉진요인과 억제요인의 영향 분석
  • See-Saw 분석

제5장 정맥주사제 유형별 시장, 2021-2031

  • 시장 개요
  • 성장 및 매출 분석 : 2022 vs. 2031
  • 시장 세분화
    • 부분 비경구 영양
      • 연령층
    • 완전 비경구 영양
      • 연령층

제6장 정맥주사제 구성별 시장, 2021-2031

  • 시장 개요
  • 성장 및 매출 분석 : 2022 vs. 2031
  • 시장 세분화
    • 탄수화물
    • 비타민 및 미네랄
    • 단회투여 아미노산
    • 비경구 지질 에멀전
    • 기타

제7장 정맥주사제 최종사용자별 시장, 2021-2031

  • 시장 개요
  • 성장 및 매출 분석 : 2022 vs. 2031
  • 시장 세분화
    • 병원 및 진료소
    • 외래수술센터(ASC)
    • 가정치료 환경

제8장 북미의 정맥주사제 시장, 2021-2031

  • 시장 개요
  • 정맥주사제 유형별 시장, 2021-2031
  • 정맥주사제 구성별 시장, 2021-2031
  • 정맥주사제 최종사용자별 시장, 2021-2031
  • 정맥주사제 지역별 시장, 2021-2031
    • 북미
      • 미국
      • 캐나다
      • 기타 북미

제9장 영국 및 유럽연합의 정맥주사제 시장, 2021-2031

  • 시장 개요
  • 정맥주사제 유형별 시장, 2021-2031
  • 정맥주사제 구성별 시장, 2021-2031
  • 정맥주사제 최종사용자별 시장, 2021-2031
  • 정맥주사제 지역별 시장, 2021-2031
    • 영국 및 유럽연합
      • 영국
      • 독일
      • 스페인
      • 이탈리아
      • 프랑스
      • 기타 유럽

제10장 아시아태평양의 정맥주사제 시장, 2021-2031

  • 시장 개요
  • 정맥주사제 유형별 시장, 2021-2031
  • 정맥주사제 구성별 시장, 2021-2031
  • 정맥주사제 최종사용자별 시장, 2021-2031
  • 정맥주사제 지역별 시장, 2021-2031
    • 아시아태평양
      • 중국
      • 일본
      • 인도
      • 호주
      • 한국
      • 기타 아시아태평양

제11장 라틴아메리카의 정맥주사제 시장, 2021-2031

  • 시장 개요
  • 정맥주사제 유형별 시장, 2021-2031
  • 정맥주사제 구성별 시장, 2021-2031
  • 정맥주사제 최종사용자별 시장, 2021-2031
  • 정맥주사제 지역별 시장, 2021-2031
    • 라틴아메리카
      • 브라질
      • 멕시코
      • 기타 라틴아메리카

제12장 중동 및 아프리카의 정맥주사제 시장, 2021-2031

  • 시장 개요
  • 정맥주사제 유형별 시장, 2021-2031
  • 정맥주사제 구성별 시장, 2021-2031
  • 정맥주사제 최종사용자별 시장, 2021-2031
  • 정맥주사제 지역별 시장, 2021-2031
    • 중동 및 아프리카
      • GCC
      • 아프리카
      • 기타 중동 및 아프리카

제13장 기업 개요

  • Amanta Healthcare Ltd.
  • Axa Parenterals Ltd.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton Dickinson and Company
  • Eurolife Healthcare Pvt Ltd.
  • Fresenius Kabi AG
  • Grifols S.A
  • Henry Schein Inc.
  • ICU Medical Inc.
  • JW Life Science
  • Otsuka Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Salius Pharma Private Limited
  • Sichuan Kelun Pharmaceutical Co. Ltd
  • Soxa Formulations & Research(Pvt.) Ltd.
  • Vifor Pharma Management Ltd.
  • 기타
LSH 23.06.15

Intravenous Solutions Market is Expected to Grow at 8.0% by 2031. Intravenous solutions present a combination of nutrients that support patients to get essential nutrition. The demand for intravenous solutions on the global front is undergoing steady growth and its market presents a higher growth in the Asia-Pacific region. Intravenous products are highly regulated for quality and availability assurance. Though matured, this market has been undergoing continuous evolution, thus experiencing steady growth.

The intravenous solutions manufacturers and vendors worldwide are perpetually improving the nature of products, and sales and distribution methods respectively. Several large players have employed direct sales force and independent distributors, retail and wholesalers. Alternate modes of supply are also employed by the manufacturers to retain profitability. Third parties that store and deliver products for the manufacturer have a significant foothold in developed markets. These type of vendors are found to better cater swift customer service as they always stock adequate inventories. Other sales practices in this market include sales through customer and sales service representatives, catalogue circulation and merchandising, electronic purchase facility and allied benefits, e-mail campaign, publicity through trade publications and trade fairs and others.

Market Players

Amanta Healthcare Ltd., Axa Parenterals Ltd., B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, Eurolife Healthcare Pvt Ltd.,Fresenius Kabi AG, Grifols S.A, Henry Schein Inc., ICU Medical, Inc., JW Life Science, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Salius Pharma Private Limited, Sichuan Kelun Pharmaceutical Co. Ltd, Soxa Formulations & Research (Pvt.) Ltd., Vifor Pharma Management Ltd. And Other Notable Players.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Intravenous Solutions market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Intravenous Solutions market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Type

  • Partial Parenteral Nutrition
    • Age Group
    • Pediatric
    • Adult
  • Total Parenteral Nutrition
    • Age Group
    • Pediatric
    • Adult

Composition

  • Carbohydrates
  • Vitamins and Minerals
  • Single Dose Amino Acids
  • Parenteral Lipid Emulsion
  • Others

End Users

  • Hospitals and Clinics
  • Ambulatory Surgery Centers
  • Home care settings

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Intravenous Solutions market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Intravenous Solutions market?
  • Which is the largest regional market for Intravenous Solutions market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Intravenous Solutions market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Intravenous Solutions market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Intravenous Solutions Market
  • 2.2. Global Intravenous Solutions Market, By Type, 2022 (US$ Million)
  • 2.3. Global Intravenous Solutions Market, By Composition, 2022 (US$ Million)
  • 2.4. Global Intravenous Solutions Market, By End Users, 2022 (US$ Million)
  • 2.5. Global Intravenous Solutions Market, By Geography, 2022 (US$ Million)
  • 2.6. Attractive Investment Proposition by Geography, 2022

3. Intravenous Solutions Market: Competitive Analysis

  • 3.1. Market Positioning of Key Intravenous Solutions Market Vendors
  • 3.2. Strategies Adopted by Intravenous Solutions Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Intravenous Solutions Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Intravenous Solutions Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Partial Parenteral Nutrition
      • 5.3.1.1. Age Group
        • 5.3.1.1.1. Pediatric
        • 5.3.1.1.2. Adult
    • 5.3.2. Total Parenteral Nutrition
      • 5.3.2.1. Age Group
        • 5.3.2.1.1. Pediatric
        • 5.3.2.1.2. Adult

6. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Carbohydrates
    • 6.3.2. Vitamins and Minerals
    • 6.3.3. Single Dose Amino Acids
    • 6.3.4. Parenteral Lipid Emulsion
    • 6.3.5. Others

7. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 7.3. Market Segmentation
    • 7.3.1. Hospitals and Clinics
    • 7.3.2. Ambulatory Surgery Centers
    • 7.3.3. Home care settings

8. North America Intravenous Solutions Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
  • 8.3. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
  • 8.4. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
  • 8.5.Intravenous Solutions Market: By Region, 2021-2031, USD (Million)
    • 8.5.1.North America
      • 8.5.1.1. U.S.
        • 8.5.1.1.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 8.5.1.1.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 8.5.1.1.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 8.5.1.2. Canada
        • 8.5.1.2.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 8.5.1.2.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 8.5.1.2.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 8.5.1.3. Rest of North America
        • 8.5.1.3.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 8.5.1.3.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 8.5.1.3.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

9. UK and European Union Intravenous Solutions Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
  • 9.3. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
  • 9.4. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
  • 9.5.Intravenous Solutions Market: By Region, 2021-2031, USD (Million)
    • 9.5.1.UK and European Union
      • 9.5.1.1. UK
        • 9.5.1.1.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.1.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.1.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 9.5.1.2. Germany
        • 9.5.1.2.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.2.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.2.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 9.5.1.3. Spain
        • 9.5.1.3.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.3.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.3.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 9.5.1.4. Italy
        • 9.5.1.4.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.4.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.4.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 9.5.1.5. France
        • 9.5.1.5.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.5.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.5.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 9.5.1.6. Rest of Europe
        • 9.5.1.6.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.6.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.6.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

10. Asia Pacific Intravenous Solutions Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
  • 10.3. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
  • 10.4. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
  • 10.5.Intravenous Solutions Market: By Region, 2021-2031, USD (Million)
    • 10.5.1.Asia Pacific
      • 10.5.1.1. China
        • 10.5.1.1.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.1.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.1.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 10.5.1.2. Japan
        • 10.5.1.2.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.2.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.2.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 10.5.1.3. India
        • 10.5.1.3.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.3.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.3.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 10.5.1.4. Australia
        • 10.5.1.4.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.4.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.4.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 10.5.1.5. South Korea
        • 10.5.1.5.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.5.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.5.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 10.5.1.6. Rest of Asia Pacific
        • 10.5.1.6.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.6.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.6.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

11. Latin America Intravenous Solutions Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
  • 11.3. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
  • 11.4. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
  • 11.5.Intravenous Solutions Market: By Region, 2021-2031, USD (Million)
    • 11.5.1.Latin America
      • 11.5.1.1. Brazil
        • 11.5.1.1.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 11.5.1.1.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 11.5.1.1.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 11.5.1.2. Mexico
        • 11.5.1.2.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 11.5.1.2.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 11.5.1.2.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 11.5.1.3. Rest of Latin America
        • 11.5.1.3.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 11.5.1.3.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 11.5.1.3.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

12. Middle East and Africa Intravenous Solutions Market, 2021-2031, USD (Million)

  • 12.1. Market Overview
  • 12.2. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
  • 12.3. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
  • 12.4. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
  • 12.5.Intravenous Solutions Market: By Region, 2021-2031, USD (Million)
    • 12.5.1.Middle East and Africa
      • 12.5.1.1. GCC
        • 12.5.1.1.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 12.5.1.1.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 12.5.1.1.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 12.5.1.2. Africa
        • 12.5.1.2.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 12.5.1.2.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 12.5.1.2.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 12.5.1.3. Rest of Middle East and Africa
        • 12.5.1.3.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 12.5.1.3.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 12.5.1.3.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

13. Company Profile

  • 13.1. Amanta Healthcare Ltd.
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Portfolio
    • 13.1.4. Strategic Initiatives
  • 13.2. Axa Parenterals Ltd.,
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Portfolio
    • 13.2.4. Strategic Initiatives
  • 13.3. B. Braun Melsungen AG
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Portfolio
    • 13.3.4. Strategic Initiatives
  • 13.4. Baxter International Inc.
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Portfolio
    • 13.4.4. Strategic Initiatives
  • 13.5. Becton, Dickinson and Company
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Portfolio
    • 13.5.4. Strategic Initiatives
  • 13.6. Eurolife Healthcare Pvt Ltd.
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Portfolio
    • 13.6.4. Strategic Initiatives
  • 13.7. Fresenius Kabi AG
    • 13.7.1. Company Overview
    • 13.7.2. Financial Performance
    • 13.7.3. Product Portfolio
    • 13.7.4. Strategic Initiatives
  • 13.8. Grifols S.A
    • 13.8.1. Company Overview
    • 13.8.2. Financial Performance
    • 13.8.3. Product Portfolio
    • 13.8.4. Strategic Initiatives
  • 13.9. Henry Schein Inc.
    • 13.9.1. Company Overview
    • 13.9.2. Financial Performance
    • 13.9.3. Product Portfolio
    • 13.9.4. Strategic Initiatives
  • 13.10. ICU Medical, Inc.
    • 13.10.1. Company Overview
    • 13.10.2. Financial Performance
    • 13.10.3. Product Portfolio
    • 13.10.4. Strategic Initiatives
  • 13.11. JW Life Science
    • 13.11.1. Company Overview
    • 13.11.2. Financial Performance
    • 13.11.3. Product Portfolio
    • 13.11.4. Strategic Initiatives
  • 13.12. Otsuka Pharmaceutical Co., Ltd.
    • 13.12.1. Company Overview
    • 13.12.2. Financial Performance
    • 13.12.3. Product Portfolio
    • 13.12.4. Strategic Initiatives
  • 13.13. Pfizer, Inc.
    • 13.13.1. Company Overview
    • 13.13.2. Financial Performance
    • 13.13.3. Product Portfolio
    • 13.13.4. Strategic Initiatives
  • 13.14. Salius Pharma Private Limited
    • 13.14.1. Company Overview
    • 13.14.2. Financial Performance
    • 13.14.3. Product Portfolio
    • 13.14.4. Strategic Initiatives
  • 13.15. Sichuan Kelun Pharmaceutical Co. Ltd
    • 13.15.1. Company Overview
    • 13.15.2. Financial Performance
    • 13.15.3. Product Portfolio
    • 13.15.4. Strategic Initiatives
  • 13.16. Soxa Formulations & Research (Pvt.) Ltd.
    • 13.16.1. Company Overview
    • 13.16.2. Financial Performance
    • 13.16.3. Product Portfolio
    • 13.16.4. Strategic Initiatives
  • 13.17. Vifor Pharma Management Ltd.
    • 13.17.1. Company Overview
    • 13.17.2. Financial Performance
    • 13.17.3. Product Portfolio
    • 13.17.4. Strategic Initiatives
  • 13.18. Other Notable Players
    • 13.18.1. Company Overview
    • 13.18.2. Financial Performance
    • 13.18.3. Product Portfolio
    • 13.18.4. Strategic Initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제